A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 Administered With and Without a Spacer, and With and Without Oral Charcoal
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Pearl Therapeutics
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 21 Mar 2018 Planned End Date changed from 5 Feb 2018 to 10 May 2018.
- 21 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.